PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of ArrangementNovember 26, 2025 7:00 AM EST | Source: PreveCeutical Medical Inc.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") and BioGene Therapeutics Inc. ("BioGene"), are pleased to announce that, further ...

Core Viewpoint - PreveCeutical Medical Inc. has entered into a definitive arrangement agreement to spin out 12,000,000 common shares of its subsidiary BioGene Therapeutics Inc. to its shareholders through a share capital reorganization [1][2]. Group 1: Arrangement Details - The existing common shares of PreveCeutical will be renamed as Class A common shares, and a new class of voting common shares will be created [2]. - Each PreveCeutical Class A Share will be exchanged for one New PreveCeutical Share, with the BioGene Spinout Shares distributed on a pro rata basis [2]. - Post-arrangement, shareholders will own shares in both BioGene and PreveCeutical, with BioGene focusing on Dual Gene Therapy and PreveCeutical on preventive and curative therapies [2]. Group 2: Approval Process - The arrangement requires approval from the Supreme Court of British Columbia and a two-thirds affirmative vote from PreveCeutical shareholders at the annual general and special meeting scheduled for October 10, 2025 [3][5]. - Following shareholder and court approval, the board will set an effective date for the arrangement [3]. Group 3: Trading and Compliance - New PreveCeutical Shares will continue trading on the Canadian Securities Exchange, OTCQB, and Frankfurt Stock Exchange, while BioGene Shares will not be listed on any exchange but will be a reporting issuer in British Columbia, Alberta, and Ontario [4]. - BioGene will comply with continuous disclosure obligations under applicable Canadian securities laws [4]. Group 4: Company Overview - PreveCeutical is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature identical products [7]. - The company has five research and development programs, including dual gene therapy for diabetes and obesity, Nature Identical™ peptides, and non-addictive analgesic peptides [7].